An official website of the United States government
Home
Name
Adstiladrin
Alternate Names
Instiladrin
Nadofaragene firadenovec-vncg
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Gene therapy
NSC Number
None
Primary Site
bladder
Histology
None
Remarks
December 16, 2022: FDA approved nadofaragene firadenovec-vncg (Adstiladrin) for adult patients with high-risk Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Coding
This drug should be coded
